Article: article from journal or magazin.
Review (review): journal as complete as possible of one specific subject, written based on exhaustive analyses from published work.
Les connectivites: progrès thérapeutiques et place de la biothérapie [Connective tissue diseases: news in therapy, role of biologics agents].
Revue Médicale Suisse
Publication types: English Abstract ; Journal ArticlePublication Status: ppublish. PDF type: mise au point
Systemic lupus erythematosus and primary Sjögren's syndrom are the two major connective tissue diseases. A better knowledge of their physiopathology allows us today to propose an adapted therapy. Moreover progress concerns the oldest treatment, hydroxychloroquine, and biotherapy. Hydroxychloroquine is still an actual treatment for lupus, its positive effects are better understood today. Nevertheless it does not seem to be efficient to treat primitive Sjögren. Biotherapy targeting B lymphocytes seems efficient in these two connective tissue diseases. Anti TNF therapy is not recommended and seems to induce connective tissue diseases. The real news is the recent approval and reimbursement in Switzerland of the new drug belimumab (Benlysta) in case of moderate lupus.
Antibodies, Monoclonal/therapeutic use, B-Lymphocytes/metabolism, Connective Tissue Diseases/drug therapy, Connective Tissue Diseases/physiopathology, Drug Approval, Humans, Hydroxychloroquine/therapeutic use, Immunologic Factors/therapeutic use, Lupus Erythematosus, Systemic/drug therapy, Lupus Erythematosus, Systemic/physiopathology, Sjogren's Syndrome/drug therapy, Sjogren's Syndrome/physiopathology, Switzerland
Last modification date